|
December 17, 2024 – Radiological and Nuclear Emergencies – 1.5 hours
Dr. Zaid Kazzi from Emory University and Andrew King, Director of the Michigan Poison and Drug Information Center, will discuss radiological and nuclear emergencies and how they will cause unprecedented strain on healthcare and public health systems. Emergency preparedness for such events require specialized resources and tools that require a multidisciplinary collaboration.
Who should attend:
EMS, Healthcare Coalitions, Hospitals, Long-Term Care, Local Emergency Management, Health Departments, Tribes, etc.
he Cybersecurity and Infrastructure Security Agency (CISA) offers a wide range of free tools and services to help organizations address their cybersecurity needs. One of the services provided by CISA is its vulnerability scanning tool, which regularly monitors and assesses internet-connected assets to evaluate their security health. This tool checks for thousands of vulnerabilities, weak configurations, configuration errors, and poor security practices. By enrolling in CISA’s vulnerability scanning tool, critical infrastructure owners and operators can make prioritized decisions to protect their assets from cyber threats and disruptions, while also identifying vulnerabilities, improving response strategies, and significantly reducing risk—all of which strengthen defenses against evolving cyber threats.
Registration is now open for the NACCHO 2025 Integrated Foodborne Outbreak Response and Management Regional Meetings
The Administration for Strategic Preparedness and Response (ASPR) announced on Monday, November 25, 2024, two new agreements under the Defense Product Act Title III authority in an effort to strengthen the US health supply chain.
Under these agreements, ASPR’s Office of Industrial Base Management and Supply Chain (IBMSC) will provide $44.4 million to two companies: $32.4 million to Manus Bio, Inc, a private company in Waltham, Massachusetts, to expand its facilities in preparation for production of the key starting material for artemisinin, an antimalarial drug. Under the second agreement, ASPR IBMSC will provide up to $12 million to Antheia Incorporated of Menlo, California, to produce oripavine, which is used to produce several essential medicines including analgesics and anti-seizure medications. These medicines are periodically in shortage and may be used during health emergencies. The agreements announced today will reduce U.S. reliance on foreign sources.
These funding awards were made through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP Consortium), managed by Advanced Technologies International under an Other Transaction Authority agreement with ASPR’s Biomedical Advanced Research and Development Authority. Please see the news release or contact the ASPR press office for more information.
|
